What does it take to scale a career across the global pharmaceutical industry over 38 years? In this podcast, N. Chandrasekaran, Associate Vice President at NATCO Pharma (Ex-Sandoz, Ex-Novartis, Ex-Biocon), breaks down the unwritten rules of corporate pharma growth, commercial sales team execution, and executive leadership.

If you are a Medical Representative (MR), Area Business Manager (ABM), or pharmaceutical professional looking to grow into executive positions, this episode provides a practical blueprint.

Chandrasekaran shares a contrarian take on corporate culture, declaring organization culture a myth and explaining why leadership rests entirely with line managers. He details how to manage remote field teams over Zoom, leverage the 5W blueprint to convert raw effort into sales goals, and apply the golden rule of executive communication: praise in public, critique in private.

Looking for a proven pharma sales strategy, a clear career growth plan, or actionable team management advice from top life sciences executives? This detailed discussion covers pharmaceutical commercial operations, MNC vs Indian pharma corporate frameworks, and field force execution metrics.

Learn how to navigate the shift from entry-level medical representative roles to high-level regional manager positions, track field force effort logs without micro-managing, pitch high-priced innovator molecules, and use the 5W framework to align remote field teams over online meetings.

Connect with N. Chandrasekaran on LinkedIn: / n-chandrasekaran-23b73572

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

Website: https://gameofpharma.com/

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

CONNECT WITH HOST - LOKESH SHARMA

LinkedIn: / lokesh-sharma-7250a71a9

FOLLOW GAME OF PHARMA:

LinkedIn: / game-of-pharma-podcast

Instagram: / gameofpharma

How do you survive and dominate an Indian pharma market where 60,000 generic brands launch every single year? Dr. Vijay Charlu (President - India Business, Corona Remedies Limited) breaks down the ultimate playbook for molecule selection, market disruption, and successful brand acquisitions.

The rules of the pharmaceutical industry have fundamentally shifted. Traditional marketing is dead, and market disruption is the new norm. In this episode of Game of Pharma, we sit down with Dr. Vijay Charlu to uncover why scaling matters more than product value, how to spot portfolio gaps, and the real reason most private equity pharma acquisitions fail (Hint: It’s not the money).

If you are a pharma executive, marketer, entrepreneur, or investor looking to understand the mechanics of the Indian drug market, this masterclass is for you.

If you found this breakdown valuable, don't forget to Like, Subscribe, and hit the Notification Bell to stay ahead of the curve in the pharma ecosystem!

Connect with Dr. Vijay Charlu on LinkedIn: / vijaycharlu

LISTEN ON PODCAST:

Apple Podcasts: https://podcasts.apple.com/us/podcast...

Spotify: https://open.spotify.com/show/4EDgDoe...

GAME OF PHARMA NEWSLETTER:

Weekly pharma insights delivered to your inbox

Subscribe: https://game-of-pharma.beehiiv.com

Host LinkedIn - / lokesh-sharma-7250a71a9

Follow us on social media -

Website : https://gameofpharma.com/

Instagram : https://www.instagram.com/gameofpharm...

LinkedIn : / game-of-pharma-podcast

What really makes a pharma brand succeed?

Is it the molecule?

The marketing budget?

Or the people on the ground?

In this episode of Leaders of Pharma, we have Sumit Bhattacharjee, who started his journey as a Medical Representative in 1990 and went on to work across Nicholas Piramal, UCB, Dr. Reddy’s, Zydus Cadila, and now Exeltis India.

With 36 years of hands on experience, he shares what actually works in pharma marketing→ building trust with doctors, strengthening retailer relationships, empowering field teams, and adapting to the rise of generics and e-pharmacies.

This conversation is practical, and rooted in real industry experience.

If you are a Medical Representative, Pharma Marketer, or someone trying to understand how this industry truly works,then this episode is for you.

Watch the episode and let us know:

What do you think matters more in pharma - product, promotion, or people?

Guest LinkedIn - / sumit-bhattacharjee-6b0a8315

Host LinkedIn - / lokesh-sharma-7250a71a9

Follow us on social media -

Website : https://gameofpharma.com/

Instagram : https://www.instagram.com/gameofpharm...

LinkedIn : / game-of-pharma-podcast

The obesity market is experiencing the most explosive growth in modern pharmaceutical history. With the rise of GLP-1 medications and a flood of semaglutide generics entering the market, the landscape is shifting from clinical discovery to a massive battle for market access and positioning.

In this episode of Game of Pharma, Lokesh sits down with Dr. Evan Nadler to decode the reality of this multi-billion-dollar therapeutic gold rush. We move past the consumer hype and break down the commercial realities of metabolic treatments.

In this episode, we cover:

• The GLP-1 Gold Rush: How the massive surge in obesity therapeutics is fundamentally changing pharmaceutical brand strategy.
• The Access Gap: Why the gap in treatment access is the single biggest opportunity (and hurdle) in healthcare right now.
• US vs. India: Comparing the structural differences between the US and Indian markets regarding metabolic therapies.
• Semaglutide Positioning: How pharma companies must position their branded generics to win the long game in a highly saturated market.

Whether you are a pharma marketer, brand manager, or healthcare executive, this conversation provides a strategic roadmap for navigating the biggest market shift in a generation.

#PharmaStrategy #GLP1 #ObesityMarket #PharmaMarketing #HealthcareInnovation #GameOfPharma #Semaglutide #BestPharmaPodcast

Dr. Nadler's LinkedIn: https://www.linkedin.com/in/evanpnadler/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/

Most people still think of China as just a generics producer. They are dead wrong. In just one decade, China has transformed from "copycat" to cutting-edge, and now Big Pharma is licensing assets from China, not just to it.

In this episode of Game of Pharma, Lokesh sits down with Dr. Julien Willard, former senior intelligence officer, health economist, and strategy executive at Accenture and IBM, to decode what is really happening in global biotech.

In this episode, we cover:

• The Big Shift: The single biggest sign China's pharma industry has fundamentally changed.
• The Gold Rush: Why global pharmaceutical companies are scrambling for Chinese biotech assets.
• Speed to Market: How clinical trials that take years in the West are being executed in months in Shanghai.
• The US vs. China: What Western pharma should (and absolutely shouldn't) copy from China's aggressive playbook.

If you make decisions in pharma, biotech, healthcare strategy, or investment, this conversation will change how you see the next decade of the industry.

#PharmaStrategy #BiotechTrends #ClinicalTrials #HealthcareInvestment #PharmaMarketing #DrugDevelopment #Pharma #Biotech #Pharmaceuticals #LifeSciences #HealthcareInnovation

Julien's LinkedIn: https://www.linkedin.com/in/julienwillard/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/

The future of clinical trials and pharmacovigilance relies heavily on patient data, but integrating that data is a massive challenge. With countless touchpoints and messy data formats across different devices, how can the pharmaceutical industry actually make sense of it all?

In this episode of Game of Pharma, Lokesh sits down with Marco Benitez, the CEO and founder of ROOK. Marco brings a wealth of experience to the table, having previously served as the Head of Medical Affairs at Roche before founding his tech company. We dive deep into how ROOK is solving the healthcare industry's fragmented data problem.

In this episode, we cover:

• The ROOK API Solution: How ROOK integrates data from over 300 wearables—including Apple Watch, Polar, Garmin, and Huawei—into a single API platform.
• Data Harmonization: The process of cleaning, standardizing, and harmonizing wearable data so that it is AI-ready for clinical trials and insurance companies.
• The Big Pivot: How the pandemic forced ROOK to pivot from a fitness club hardware model (tracking heart rates on screens) into a massive B2B data science company.
• Marco's Journey: Marco shares his incredible entrepreneurial path, starting from building a hospital algorithm at just 19 years old, to navigating Big Pharma, to pitching his multi-billion dollar data vision.
• 
  

If you are working in clinical trials, healthcare tech, or digital strategy, this episode provides a clear roadmap on how unstructured wearable data is being transformed into actionable insights.

#WearableTech #ClinicalTrials #DigitalHealth #PharmaInnovation #HealthData #GameOfPharma

Marco's LinkedIn: https://www.linkedin.com/in/marcobzg/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/

What does real omnichannel marketing look like in today’s pharma world?

In this episode of Game of Pharma, we sit down with Nick Smith—Founder of Loud Canvas Health and ex-Eversana leader, to unpack what’s changed in pharma omnichannel, why personalization beats presence, and how behavior data can reshape brand strategy.

Nick has worked on both niche and large-scale brands and shares powerful insights on:

• Aligning brand goals with HCP and payer behavior
• Creating omnichannel journeys that actually convert
• Why rep visits are still gold (if tracked right)
• Structuring websites for different stakeholders
• Using omnichannel maturity models to future-proof brand plans
• 
  

Whether you're in brand, marketing, or access strategy, this episode will challenge the way you think about omnichannel in pharma.

Don’t forget to like, and hit the follow icon to stay updated with new episodes!

#OmnichannelMarketing #PharmaMarketing #HealthcareStrategy #GameOfPharma #NickSmith #DigitalHealth #PatientCentric #HCPengagement #PayerStrategy #MarketingPodcast

Nick's LinkedIn: https://www.linkedin.com/in/therealnicksmith/

Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/

Follow us on social media-

Website: https://gameofpharma.com/

Instagram: https://www.instagram.com/gameofpharma/

LinkedIn: https://www.linkedin.com/company/game-of-pharma/